Statins Do Not Reduce Bone-Building Benefits of teriparatide in Severe Osteoporosis: Study
Researchers have found in a new study that Statin use does not hinder the anabolic efficacy of recombinant human parathyroid hormone (rhPTH) in improving bone mineral density (BMD) among postmenopausal women with severe osteoporosis.
They reported that statins do not reduce the bone-building effects of teriparatide in older women with severe osteoporosis. Instead, the study found that statins may add complementary antiresorptive benefits, strengthening the case for their continued use in this patient population. The findings provide reassurance for clinicians and patients who often manage both cardiovascular and skeletal health concerns concurrently.
The analysis, published in The Journal of Clinical Endocrinology & Metabolism, assessed outcomes in women undergoing teriparatide therapy while also taking statins for lipid management.
Results demonstrated that bone anabolism induced by teriparatide was preserved, with no evidence of interference from statin use. At the same time, markers of bone resorption showed additional improvements, suggesting that statins may provide a synergistic effect when combined with teriparatide. This dual action highlights the potential advantage of managing osteoporosis and cardiovascular disease together without compromising therapeutic outcomes.
The authors concluded that statins not only maintain the anabolic efficacy of teriparatide but also contribute supplementary antiresorptive benefits. These results reinforce the safety of combining statins with osteoporosis treatment regimens and suggest that patients may gain broader health advantages from this overlap in therapy.
The study supports the integration of statin therapy in women with severe osteoporosis receiving teriparatide, ensuring that cardiovascular protection and skeletal benefits can be pursued simultaneously.
Reference
Oliveri, Cecilia, et al. "Statins Do Not Affect Bone Anabolism in Older Women Treated With Teriparatide." The Journal of Clinical Endocrinology and Metabolism, 2025.
